KIDS · Orthopediatrics Corp
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. OrthoPediatrics posted record Q2 2026 revenue of $70.5M (+15% YoY) driven by 26% Trauma & Deformity growth, raised full-year 2026 revenue guidance to $265–$269M (12–14% growth), and reiterated ~$25M adjusted EBITDA and full-year free-cash-flow breakeven targets while delivering a record $6.8M adjusted EBITDA and a 78% reduction in free-cash-flow usage.
- + Trauma & Deformity revenue grew 26% YoY to $52.6M, driven by share gains, OPSB, and early super-cycle product contributions
- + Record adjusted EBITDA of $6.8M (vs. $4.1M prior year) with margin of nearly 10%
- + Free cash flow usage improved 78% YoY to $3.1M used, supporting reaffirmed full-year free-cash-flow breakeven goal
- + Gross margin expanded to 74% from 72% on favorable mix
- + International revenue grew 22% YoY to a record $15.7M on European strength, with EU MDR approvals expected to drive further growth
- − Scoliosis revenue declined 9% YoY to $16.9M due to zero 7D unit sales and lower Brazil/international set sales
- − GAAP net loss widened to $7.2M and non-GAAP net loss per share of $0.26 worse than $0.11 prior year due to FX
- − Total other expense of $2.9M vs. other income of $3.6M prior year on Euro weakness and higher interest expense
- − Adjusted EBITDA guidance of ~$25M held flat despite H1 outperformance, suggesting conservatism and potential headwinds in H2
- − Q3/Q4 revenue expected to be sequentially lower than Q2 due to timing of capital placements and 7D units
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KIDS
this stock
Orthopediatrics Corp
|
$588.78M | +22.1% | +37.9% | — | 3.4% |
|
ABT
Abbott Laboratories
|
$174.90B | -22.8% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.0% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -22.3% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.7% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KIDS | -4.2% | -4.9% | +35.8% | -2.6% | +22.1% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -3.8% | -4.7% | +23.4% | -2.8% | +10.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.